• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>other >Effects of Urinary Kallidinogenase on NIHSS score mRS score and fasting glucose levels in acute ischemic stroke patients with abnormal glucose metabolism
【2h】

Effects of Urinary Kallidinogenase on NIHSS score mRS score and fasting glucose levels in acute ischemic stroke patients with abnormal glucose metabolism

机译：尿钙调蛋白原酶对糖代谢异常的急性缺血性卒中患者NIHSS评分mRS评分和空腹血糖水平的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Urinary kallidinogenase may assist recovery acute ischemic stroke. This study evaluated the effect of urinary kallidinogenase on National Institute of Health Stroke Scale (NIHSS) score, modified Rankin scale (mRS) score, and fasting glucose levels in patients with acute ischemic stroke (AIS) combined with diabetes mellitus and impaired fasting glucose.Patients with AIS and abnormal glucose metabolism were enrolled in this prospective cohort study and divided into 2 groups. The human urinary kallidinogenase (HUK) group were treated with urinary kallidinogenase and standard treatment; the control group received standard treatment. NIHSS scores, mRS scores, and fasting blood glucose were evaluated and compared.A total of 113 patients were included: 58 in the HUK group and 55 in the control group. NIHSS scores decreased with treatment in both groups (time effect P < .05), but were lower in the HUK group (main effect P = .026). The mRS score decreased in both groups from 10 until 90 days after treatment (time effect P < .05); the 2 groups were similar (main effect, P = .130). Blood glucose levels decreased in both groups 10 days after treatment (time effect, P < .05), but there was no significant treatment effect (main effect, P = .635). Multivariate analysis showed blood uric acid >420 μmol/L (odds ratio [OR]: 0.053, 95% confidence interval [CI]: 0.008–0.350; P = .002) and application of HUK (OR: 0.217, 95% CI: 0.049–0.954; P = .043) were associated with 90% NIHSS recovery. Baseline NIHSS score was independently associated with poor curative effect.Urinary kallidinogenase with conventional therapy significantly improved NIHSS scores in patients with AIS. Urinary kallidinogenase also showed a trend toward lower fasting blood glucose levels, although the level did not reach significance.
机译：尿激肽原酶可能有助于恢复急性缺血性中风。这项研究评估了急性缺血性中风（AIS）合并糖尿病和空腹血糖受损的患者中，尿中的kallidinogenase对国立卫生研究院卒中量表（NIHSS）评分，改良的兰金量表（mRS）评分和空腹血糖水平的影响。这项前瞻性队列研究纳入了AIS和糖代谢异常的患者，分为2组。对人尿激肽原酶（HUK）组进行尿激肽原酶的常规治疗。对照组接受标准治疗。评估并比较了NIHSS评分，mRS评分和空腹血糖。共纳入113例患者：HUK组58例，对照组55例。两组的NIHSS得分均随治疗而降低（时间效应P <.05），而在HUK组中NIHSS分数较低（主效应P = .026）。两组的mRS评分从治疗后的10天到90天均降低（时间效应P <0.05）；两组相似（主效应，P = .130）。两组在治疗后10天的血糖水平均下降（时间效应，P <0.05），但没有明显的治疗作用（主效应，P = .635）。多变量分析显示血尿酸> 420μmol/ L（几率[OR]：0.053，95％置信区间[CI]：0.008-0.350； P = .002）和HUK的应用（OR：0.217，95％CI： 0.049–0.954； P = .043）与90％的NIHSS回收率相关。基线NIHSS评分与疗效差独立相关。常规疗法中的尿激肽酶原酶可显着改善AIS患者的NIHSS评分。尿激肽原酶还显示出降低空腹血糖水平的趋势，尽管该水平没有达到显着水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号